News

GlobalData on MSN4d

Schrödinger ends development of blood cancer drug after patient deaths

Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...
Targeted Oncology2h

Global Phase 3 Trial of Lisaftoclax Cleared for Higher-Risk MDS

A groundbreaking phase 3 study for lisaftoclax offers hope for first-line treatment of higher-risk myelodysplastic syndrome, ...
HealthDay on MSN5d

Few With Myelodysplastic Syndromes Receive Hypomethylating Agents

Few patients with MDS receive treatment with hypomethylating agents, with evidence of age-, sex-, and race-related disparities.
Targeted Oncology5d

Changing the Biology of Myelodysplastic Syndromes With Luspatercept

New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.
The American Journal of Managed Care3h

TNX-102 SL Now Fourth FDA-Approved Treatment for Fibromyalgia

This approval brings the total to 4 of medications approved to treat fibromyalgia; in addition to cyclobenzaprine HCl ...
MPR6d

FDA Restricts Skysona Use After More Reports of Hematologic Malignancy

Approved in 2022, Skysona is indicated to slow the progression of neurologic dysfunction in boys 4 to 17 years of age with early, active cerebral adrenoleukodystrophy.